Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolLON:HIK
CUSIPN/A
Phone+44-20-73992760
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins7.82%
Return on Equity5.69%
Return on Assets3.19%
Miscellaneous
EmployeesN/A
Outstanding Shares240,660,000
Market Cap£2.67 billion
Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions
What is Hikma Pharmaceuticals' stock symbol?
Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."
How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?
Hikma Pharmaceuticals declared a dividend on Wednesday, August 15th. Stockholders of record on Thursday, August 23rd will be given a dividend of GBX 0.12 per share on Friday, September 21st. This represents a dividend yield of 0.53%. The ex-dividend date of this dividend is Thursday, August 23rd. The official announcement can be viewed at this link. View Hikma Pharmaceuticals' Dividend History.
What price target have analysts set for HIK?
9 equities research analysts have issued 1-year price objectives for Hikma Pharmaceuticals' shares. Their forecasts range from GBX 850 to GBX 1,950. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 1,271.33 in the next twelve months. This suggests that the stock has a possible downside of 30.1%. View Analyst Price Targets for Hikma Pharmaceuticals.
What is the consensus analysts' recommendation for Hikma Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hikma Pharmaceuticals.
Who are some of Hikma Pharmaceuticals' key competitors?
Some companies that are related to Hikma Pharmaceuticals include Merck KGaA (MRK), Valeant Pharmaceuticals Intl (VRX), Canopy Growth (WEED), Aurora Cannabis (ACB), STADA Arzneimittel (SAZ), Hikma Pharmaceuticals (HKMPY), Aphria (APH), MedReleaf (LEAF), Knight Therapeutics (KHTRF), Hydropothecary (THCX), OrganiGram (OGI), Supreme Cannabis (FIRE), Weed (BUDZ), OrganiGram (OGRMF) and Medical Marijuana (MJNA).
Who are Hikma Pharmaceuticals' key executives?
Hikma Pharmaceuticals' management team includes the folowing people:
- Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
- Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
- Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
- Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
- Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D
Has Hikma Pharmaceuticals been receiving favorable news coverage?
News stories about HIK stock have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hikma Pharmaceuticals earned a news impact score of 0.22 on Accern's scale. They also gave media headlines about the company an impact score of 46.82 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Hikma Pharmaceuticals.
How do I buy shares of Hikma Pharmaceuticals?
Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Hikma Pharmaceuticals' stock price today?
One share of HIK stock can currently be purchased for approximately GBX 1,818.
How big of a company is Hikma Pharmaceuticals?
Hikma Pharmaceuticals has a market capitalization of £2.67 billion.
How can I contact Hikma Pharmaceuticals?
Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.
MarketBeat Community Rating for Hikma Pharmaceuticals (LON HIK)
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
